These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 34694917)

  • 1. Novel Pneumococcal Protein-Polysaccharide Conjugate Vaccine Based on Biotin-Streptavidin.
    Guo M; Guo X; Zhang C; Zhu S; Zhang Y; Gu T; Kong W; Wu Y
    Infect Immun; 2022 Jan; 90(1):e0035221. PubMed ID: 34694917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines - A phase II, randomised, observer-blind study in Gambian infants.
    Odutola A; Ota MOC; Antonio M; Ogundare EO; Saidu Y; Owiafe PK; Worwui A; Idoko OT; Owolabi O; Kampmann B; Greenwood BM; Alderson M; Traskine M; Swinnen K; Verlant V; Dobbelaere K; Borys D
    Vaccine; 2019 May; 37(19):2586-2599. PubMed ID: 30975570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
    Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
    Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human monoclonal antibodies isolated from a primary pneumococcal conjugate Vaccinee demonstrates the expansion of an antigen-driven Hypermutated memory B cell response.
    Chen Z; Cox KS; Tang A; Roman J; Fink M; Kaufhold RM; Guan L; Xie A; Boddicker MA; Mcguinness D; Xiao X; Li H; Skinner JM; Verch T; Retzlaff M; Vora KA
    BMC Infect Dis; 2018 Dec; 18(1):613. PubMed ID: 30509199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies.
    da Silva MA; Converso TR; Gonçalves VM; Leite LCC; Tanizaki MM; Barazzone GC
    Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28637805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A bivalent vaccine to protect against Streptococcus pneumoniae and Salmonella typhi.
    Lu YJ; Zhang F; Sayeed S; Thompson CM; Szu S; Anderson PW; Malley R
    Vaccine; 2012 May; 30(23):3405-12. PubMed ID: 22465750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
    Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
    Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of a newly developed 13-valent pneumococcal conjugate vaccine in a mouse model.
    Park C; Kwon EY; Choi SM; Cho SY; Byun JH; Park JY; Lee DG; Kang JH; Shin J; Kim H
    Hum Vaccin Immunother; 2017 May; 13(5):1169-1176. PubMed ID: 27960627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and prospects for novel pneumococcal vaccines.
    Moffitt K; Malley R
    Hum Vaccin Immunother; 2016; 12(2):383-92. PubMed ID: 26535755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal Immunization with the Commensal
    Shekhar S; Khan R; Schenck K; Petersen FC
    Appl Environ Microbiol; 2019 Mar; 85(6):. PubMed ID: 30683742
    [No Abstract]   [Full Text] [Related]  

  • 11. Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments.
    Lu J; Sun T; Wang D; Dong Y; Xu M; Hou H; Kong FT; Liang C; Gu T; Chen P; Sun S; Lv X; Jiang C; Kong W; Wu Y
    Immunol Invest; 2015; 44(5):482-96. PubMed ID: 26107747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines.
    Poolman J; Frasch C; Nurkka A; Käyhty H; Biemans R; Schuerman L
    Clin Vaccine Immunol; 2011 Feb; 18(2):327-36. PubMed ID: 21123523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of pneumococcal vaccines over the last 10 years.
    Principi N; Esposito S
    Expert Opin Biol Ther; 2018 Jan; 18(1):7-17. PubMed ID: 29022363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new candidate epitope-based vaccine against PspA PhtD of
    Shafaghi M; Bahadori Z; Barzi SM; Afshari E; Madanchi H; Mousavi SF; Shabani AA
    Front Cell Infect Microbiol; 2023; 13():1271143. PubMed ID: 38035337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compared effectiveness of the 7-valent pneumococcal conjugate vaccine in children with the 13-valent vaccine in adults.
    Gaillat J
    Med Mal Infect; 2013 Jun; 43(6):215-21. PubMed ID: 23769155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a review of the literature.
    Cripps AW; Folaranmi T; Johnson KD; Musey L; Niederman MS; Buchwald UK
    Expert Rev Vaccines; 2021 Mar; 20(3):257-267. PubMed ID: 33567914
    [No Abstract]   [Full Text] [Related]  

  • 17. Pneumococcal conjugate vaccine for young children.
    Selman S; Hayes D; Perin LA; Hayes WS
    Manag Care; 2000 Sep; 9(9):49-52, 54, 56-7 passim. PubMed ID: 11116663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
    De Montalembert M; Abboud MR; Fiquet A; Inati A; Lebensburger JD; Kaddah N; Mokhtar G; Piga A; Halasa N; Inusa B; Rees DC; Heath PT; Telfer P; Driscoll C; Al Hajjar S; Tozzi A; Jiang Q; Emini EA; Gruber WC; Gurtman A; Scott DA
    Pediatr Blood Cancer; 2015 Aug; 62(8):1427-36. PubMed ID: 25810327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with pneumococcal elongation factor Tu enhances serotype-independent protection against Streptococcus pneumoniae infection.
    Nagai K; Domon H; Maekawa T; Hiyoshi T; Tamura H; Yonezawa D; Habuka R; Saitoh A; Terao Y
    Vaccine; 2019 Jan; 37(1):160-168. PubMed ID: 30442480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher Cytokine and Opsonizing Antibody Production Induced by Bovine Serum Albumin (BSA)-Conjugated Tetrasaccharide Related to
    Kurbatova EA; Akhmatova NK; Zaytsev AE; Akhmatova EA; Egorova NB; Yastrebova NE; Sukhova EV; Yashunsky DV; Tsvetkov YE; Nifantiev NE
    Front Immunol; 2020; 11():578019. PubMed ID: 33343566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.